User Review - Flag as inappropriate
Treatment of chronic myeloid leukemia drug - Bosutinib
The U.S. Food and Drug Administration (FDA) on September 4, 2012 approved a new "orphan drugs" Bosutinib for the treatment of chronic myeloid leukemia (CML), the latter mostly elderly onset.
Bosutinib expected to be used for other treatments including imatinib treatment intolerant or resistant chronic phase, accelerated phase or blast phase Ph chromosome-positive CML patients.
Most CML patients have mutations seen Philadelphia (Ph) chromosome, the chromosome can cause bone marrow to produce tyrosine kinases, which starts a large number of abnormal myeloid proliferation. Bosutinib by blocking tyrosine kinase signaling play a role.
Bosutinib safety and efficacy in an adult included 546 cases of patients with chronic myeloid leukemia in clinical trials has been confirmed.
Accepted Bosutinib patients most common adverse reactions include abdominal pain, diarrhea, nausea, vomiting, thrombocytopenia, rash, anemia, fever and fatigue.
FDA-approved treatment for chronic myeloid leukemia other drugs, including imatinib, dasatinib and <A href="http://www.medchemexpress.com/product/Nilotinib.html">nilotinib</a>.
Medchemexpress Can provide the above product,its website:<a href="http://www.medchemexpress.com">www.medchemexpress.com</a>
<a href="http://www.medchemexpress.com/product/Ruxolitinib-phosphate.html">Ruxolitinib phosphate</a>
<a href="http://www.medchemexpress.com/product/INCB018424-sulfate.html">INCB018424 sulfate</a>